Physicians' Academy for Cardiovascular Education

SGLT2i

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

SGLT2i improves outcomes in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD

Totality of evidence of SGLT2 inhibition in HF

3' education - Aug. 27, 2022 - Muthiah Vaduganathan, MD

All patients with HF regardless of EF benefit from SGLT2i

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022

Expanding evidence on SGLT2i: Where are we now and what can we expect?

10' education - July 21, 2022 - Prof. Scott Solomon, MD

Benefits and evolving insights on SGLT2i in the spectrum of LVEF

10' education - June 29, 2022 - Prof. Carolyn Lam, MD, PhD

Management of high risk patients with HFrEF

10' education - June 28, 2022 - Prof. Javed Butler, MD and Shelley Zieroth, MD

The clinical challenges of initiating guideline recommended therapy in HF

10' education - June 21, 2022 - Prof. John McMurray, MD

Symposium on the role of SGLT2i in tackling cardiorenal risk in diabetes

15' education - Oct. 28, 2021 - Prof. Melanie Davies, MD and prof. Nikolaus Marx, MD - Online CME

SGLT2 inhibitor benefits patients with HFpEF by reducing clinically meaningful CV events

3' education - Aug. 29, 2021 - Prof. Stefan Anker, MD, PhD

Ground-breaking HF trial with evidence for SGLT2i at EF>40%

3' education - Aug. 29, 2021 - Prof. Frank Ruschitzka, MD

Kidney and HF outcomes with SGLT2i across EF spectrum in HF

3' education - Aug. 28, 2021 - Prof. Rudolf de Boer, MD, PhD

Exciting findings of a pooled analysis of two large HF trials with SGLT2i

3' education - Aug. 27, 2021 - Milton Packer, MD

Another chapter in the SGLT2i book

3' education - Aug. 27, 2021 - Prof. Rudolf de Boer, MD, PhD

Treatment goals for patients with T2DM and CKD

10' education - July 13, 2021 - Prof. Peter Rossing, MD - Online CME

Practical challenges with SGLT2i therapy in patients with T2DM and CKD

10' education - June 29, 2021 - Alice Cheng, MD - Online CME

Clinical inertia in CKD - What is the rationale for SGLT2i?

10' education - June 21, 2021 - Janaka Karalliedde, MD, PhD - Online CME

Kidney benefit by SGLT2i may be mediated by hematocrit

5' education - June 14, 2021 - Prof. Christoph Wanner, MD

Concomitant use of diuretics and SGLT2i in HF

10' education - Mar. 23, 2021 - Prof. Patrick Rossignol, MD

Reverse cardiac remodeling by SGLT2i in non-diabetic patients with HFrEF

10' education - Feb. 22, 2021 - Carlos Santos-Gallego, MD

SGLT2 inhibitor is kidney protective, even if eGFR <30

3' education - Jan. 26, 2021 - Prof. George Bakris, MD

Novel findings with dual SGLT1 and SGLT2 inhibitor in diabetes patients

5' education - Nov. 23, 2020 - Prof. Deepak Bhatt, MD

The six pillars of therapy in HFrEF

3' education - Nov. 15, 2020 - Prof. Marc Pfeffer, MD, PhD

Incredible consistency between two SGLT2i trials in HFrEF

3' education - Sep. 7, 2020 - Milton Packer, MD

SGLT2 inhibitors: a new foundation in heart failure or another diuretic?

10' education - Sep. 1, 2020 - Prof. Rudolf de Boer, MD, PhD

Nephroprotective effects with SGLT2i in CKD patients

3' education - Aug. 30, 2020 - Prof. Hiddo Heerspink, PhD

Remarkably similar findings with another SGLT2i in HFrEF

3' education - Aug. 29, 2020 - Prof. John McMurray

Targeting cardiovascular and kidney outcomes in CKD: Where do we stand today?

10' education - July 14, 2020 - Prof. Christoph Wanner, MD

The cardiorenal connection and diabetes: Exploring intervention by SGLT2i

10' education - June 23, 2020 - Maria Rosa Costanzo, MD

SGLT2i reduces outcomes in HFmrEF and HFpEF regardless of glycemic status

3' education - Sep. 22, 2022 - Prof. Pardeep Jhund, MD, PhD

EASD 2022 "Any patient that has HFmrEF or HFpEF is going to benefit from dapaglifozin regardless of glycemic status and regardless of background diabetes therapy", says Prof. Jhund.

Effect of SGLT2i on shifts in KDIGO CKD risk groups in T2DM patients

News - Sep. 22, 2022

EASD 2022 A post-hoc analysis of EMPA-REG OUTCOME examined the effect of empagliflozin on changes in risk of progression to ESKD by assessing worsening and improvement in KDIGO risk groups.

Pilot study suggests association of sodium and protein intake with early GFR dip after SGLT2i initiation

News - Sep. 21, 2022

EASD 2022 It is not known whether a higher intake of sodium and protein may lead to a higher extent of early dip in GFR in T2DM patients who started an SGLT2 inhibitor. A pilot study was undertaken with 28 subjects.

SGLT2i improves outcomes in HFpEF and HFmrEF

3' education - Aug. 27, 2022 - Prof. Scott Solomon, MD
**ESC 2022** Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.

ESC 2022 Prof. Solomon summarizes the results of the DELIVER trial. “We believe that these data support the use of SGLT2i as foundational therapy in patients with HF, regardless of care setting or ejection fraction” said Prof. Solomon.

SGLT2i reduces primary endpoint of CV death or worsening HF in HFmrEF and HFpEF

News - Aug. 27, 2022

ESC 2022 The DELIVER trial shows that dapagliflozin reduced the risk of CV death or worsening HF in patients with HFmrEF or HFpEF, with no attenuation of treatment benefit in patients with the highest EF.

Improved outcomes with SGLT2i across entire ejection fraction range

News - Aug. 27, 2022

ESC 2022 A pooled analysis of DAPA-HF and DELIVER was undertaken to examine the effect of dapagliflozin in patient with heart failure across the entire spectrum of ejection fraction.

Two meta-analyses support prioritizing use of SGLT2i in all HF patients

News - Aug. 27, 2022

Two meta-analyses were performed including SGLT2i trials in HF patients: one including DELIVER and EMPEROR-Preserved and the other one of the 5 trials DELIVER, EMPEROR-Preserved, DAPA-HF, EMPEROR-Reduced and SOLOIST-WHF.

Totality of evidence of SGLT2 inhibition in HF

3' education - Aug. 27, 2022 - Muthiah Vaduganathan, MD
After the DELIVER trial was unblinded, two meta-analyses were performed of large SGLT2i trials in patients with HF. What are the findings and implications of these 2 meta-analyses?

ESC 2022 After the DELIVER trial was unblinded, two meta-analyses were performed of large SGLT2i trials in patients with HF. What are the findings and implications of these 2 meta-analyses?

All patients with HF regardless of EF benefit from SGLT2i

3' education - Aug. 27, 2022 - Prof. Pardeep Jhund, MD, PhD
Prof. Jhund talks about the findings and implications from a pooled analysis of DAPA-HF and DELIVER with dapagliflozin in of HF patients covering the entire LVEF spectrum.

ESC 2022 Prof. Jhund talks about the findings and implications from a pooled analysis of DAPA-HF and DELIVER with dapagliflozin in HF patients covering the entire LVEF spectrum.

E-learning When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

Accredited e-Learning

Online-CME - This course consists of 3 parts.
This course consists of 3 parts.

In this program, three speakers present the guidelines, evidence of studies and tell us what we can expect in the near future with regard to SGLT2i in heart failure.

SGLT2i attenuates longitudinal rises in CV biomarkers in T2DM patients

Literature - July 25, 2022 - Vaduganathan M, et al. - J Am Coll Cardiol. 2022

The CANVAS biomarker substudy showed that canagliflozin delays the expected increase in CV biomarkers in T2DM patients. It also reduces the risk of HF and renal disease events irrespective of biomarker levels at baseline.

Discussion - When to start using SGLT2i in HFrEF? Initiating guideline-recommended treatment options

10' education - July 21, 2022
Watch a discussion by three experts on initiating SGLT2i in HFrEF.

Watch a discussion by three experts on initiating SGLT2i in HFrEF.